

**Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, Antibody Drug Conjugate, Others), By Synthesis (Synthetic, Biotech), By Drug (Innovative, Generics), By Applications (Oncology, Hormonal, Glaucoma, Cardiovascular Disease, Diabetes, Others), By Workflow (Clinical, Commercial) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031**

Market Report | 2023-04-06 | 0 pages | Straits Research

**AVAILABLE LICENSES:**

- Single User License \$4500.00
- Global Site License \$5500.00

**Report description:**

Active Pharmaceutical Ingredients CDMO Market Analysis and Insights

The Active Pharmaceutical Ingredients CDMO Market size is anticipated to reach USD 93.42 Billion in 2022 and it is projected to reach USD 164.65 Billion by 2031, growing at a CAGR of % during the forecast period.

The Global Active Pharmaceutical Ingredients CDMO Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Active Pharmaceutical Ingredients CDMO Market growth, Size report provides a comprehensive analysis of the Healthcare IT industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing. Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Active Pharmaceutical Ingredients CDMO Market includes major supplies & Independent Consultants among others.

Global Market Scope and Active Pharmaceutical Ingredients CDMO Market

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Active Pharmaceutical Ingredients CDMO Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

#### Active Pharmaceutical Ingredients CDMO Market Country Level Analysis

The Global Active Pharmaceutical Ingredients CDMO Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Active Pharmaceutical Ingredients CDMO Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

#### Top Players in Active Pharmaceutical Ingredients CDMO Market

Some of the other major highlights of the demand for Active Pharmaceutical Ingredients CDMO Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter&rsquo;s Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Active Pharmaceutical Ingredients CDMO Market during the forecast period.

Cambrex Corporation

Recipharm AB

Thermo Fisher Scientific Inc. (Pantheon)

Corden Pharma International

Samsung Biologics

Lonza Group

Catalent, Inc.

Siegfried Holding AG

Piramal Pharma Solutions

Boehringer Ingelheim

#### Market Segmentation

The Global Active Pharmaceutical Ingredients CDMO Market Share, Demand provides the most up-to-date Healthcare IT industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

#### By Product

Traditional API

HP-API

Antibody Drug Conjugate

Others

#### By Synthesis

Synthetic

Biotech

#### By Drug

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Innovative  
Generics

By Applications

Oncology  
Hormonal  
Glaucoma  
Cardiovascular Disease  
Diabetes  
Others

By Workflow

Clinical  
Commercial

Regions Coverd

North America

U.S.  
Canada

Europe

U.K.  
Germany  
France  
Spain  
Italy  
Russia  
Nordic  
Benelux  
Rest of Europe

APAC

China  
Korea  
Japan

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

India  
Australia  
Singapore  
Taiwan  
South East Asia  
Rest of Asia-Pacific

Middle East and Africa

UAE  
Turkey  
Saudi Arabia  
South Africa  
Egypt  
Nigeria  
Rest of MEA

LATAM

Brazil  
Mexico  
Argentina  
Chile  
Colombia  
Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

**Table of Contents:**

- 1 Executive Summary
- 2 Research Scope & Segmentation
  - 2.1 Research Objectives
  - 2.2 Limitations & Assumptions
  - 2.3 Market Scope & Segmentation
  - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
  - 3.1 Emerging Regions / Countries
  - 3.2 Emerging Companies

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3.3 Emerging Applications / End Use
- 4 Market Trends
  - 4.1 Drivers
  - 4.2 Market Warning Factors
  - 4.3 Latest Macro Economic Indicators
  - 4.4 Geopolitical Impact
  - 4.5 Technology Factors
- 5 Market Assessment
  - 5.1 Porters Five Forces Analysis
  - 5.2 Value Chain Analysis
- 6 Global Active Pharmaceutical Ingredients CDMO Market Size Analysis
  - 6.1 By Product
    - 6.1.1 Traditional API
    - 6.1.2 HP-API
    - 6.1.3 Antibody Drug Conjugate
    - 6.1.4 Others
  - 6.2 By Synthesis
    - 6.2.1 Synthetic
    - 6.2.2 Biotech
  - 6.3 By Drug
    - 6.3.1 Innovative
    - 6.3.2 Generics
  - 6.4 By Applications
    - 6.4.1 Oncology
    - 6.4.2 Hormonal
    - 6.4.3 Glaucoma
    - 6.4.4 Cardiovascular Disease
    - 6.4.5 Diabetes
    - 6.4.6 Others
  - 6.5 By Workflow
    - 6.5.1 Clinical
    - 6.5.2 Commercial
- 7 North America Market Analysis
  - 7.1 By Product
    - 7.1.1 Traditional API
    - 7.1.2 HP-API
    - 7.1.3 Antibody Drug Conjugate
    - 7.1.4 Others
  - 7.2 By Synthesis
    - 7.2.1 Synthetic
    - 7.2.2 Biotech
  - 7.3 By Drug
    - 7.3.1 Innovative
    - 7.3.2 Generics
  - 7.4 By Applications
    - 7.4.1 Oncology
    - 7.4.2 Hormonal

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.4.3 Glaucoma
- 7.4.4 Cardiovascular Disease
- 7.4.5 Diabetes
- 7.4.6 Others
- 7.5 By Workflow
  - 7.5.1 Clinical
  - 7.5.2 Commercial
- 7.5 U.S.
- 7.6 Canada
- 8 Europe Market Analysis
  - 8.1 By Product
    - 8.1.1 Traditional API
    - 8.1.2 HP-API
    - 8.1.3 Antibody Drug Conjugate
    - 8.1.4 Others
  - 8.2 By Synthesis
    - 8.2.1 Synthetic
    - 8.2.2 Biotech
  - 8.3 By Drug
    - 8.3.1 Innovative
    - 8.3.2 Generics
  - 8.4 By Applications
    - 8.4.1 Oncology
    - 8.4.2 Hormonal
    - 8.4.3 Glaucoma
    - 8.4.4 Cardiovascular Disease
    - 8.4.5 Diabetes
    - 8.4.6 Others
  - 8.5 By Workflow
    - 8.5.1 Clinical
    - 8.5.2 Commercial
  - 8.5 U.K.
  - 8.6 Germany
  - 8.7 France
  - 8.8 Spain
  - 8.9 Italy
  - 8.10 Russia
  - 8.11 Nordic
  - 8.12 Benelux
  - 8.13 Rest of Europe
- 9 APAC Market Analysis
  - 9.1 By Product
    - 9.1.1 Traditional API
    - 9.1.2 HP-API
    - 9.1.3 Antibody Drug Conjugate
    - 9.1.4 Others
  - 9.2 By Synthesis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.2.1 Synthetic
- 9.2.2 Biotech
- 9.3 By Drug
  - 9.3.1 Innovative
  - 9.3.2 Generics
- 9.4 By Applications
  - 9.4.1 Oncology
  - 9.4.2 Hormonal
  - 9.4.3 Glaucoma
  - 9.4.4 Cardiovascular Disease
  - 9.4.5 Diabetes
  - 9.4.6 Others
- 9.5 By Workflow
  - 9.5.1 Clinical
  - 9.5.2 Commercial
- 9.5 China
- 9.6 Korea
- 9.7 Japan
- 9.8 India
- 9.9 Australia
- 9.10 Taiwan
- 9.11 South East Asia
- 9.12 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
  - 10.1 By Product
    - 10.1.1 Traditional API
    - 10.1.2 HP-API
    - 10.1.3 Antibody Drug Conjugate
    - 10.1.4 Others
  - 10.2 By Synthesis
    - 10.2.1 Synthetic
    - 10.2.2 Biotech
  - 10.3 By Drug
    - 10.3.1 Innovative
    - 10.3.2 Generics
  - 10.4 By Applications
    - 10.4.1 Oncology
    - 10.4.2 Hormonal
    - 10.4.3 Glaucoma
    - 10.4.4 Cardiovascular Disease
    - 10.4.5 Diabetes
    - 10.4.6 Others
  - 10.5 By Workflow
    - 10.5.1 Clinical
    - 10.5.2 Commercial
  - 10.5 UAE
  - 10.6 Turkey

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.7 Saudi Arabia
- 10.8 South Africa
- 10.9 Egypt
- 10.10 Nigeria
- 10.11 Rest of MEA
- 11 LATAM Market Analysis
  - 11.1 By Product
    - 11.1.1 Traditional API
    - 11.1.2 HP-API
    - 11.1.3 Antibody Drug Conjugate
    - 11.1.4 Others
  - 11.2 By Synthesis
    - 11.2.1 Synthetic
    - 11.2.2 Biotech
  - 11.3 By Drug
    - 11.3.1 Innovative
    - 11.3.2 Generics
  - 11.4 By Applications
    - 11.4.1 Oncology
    - 11.4.2 Hormonal
    - 11.4.3 Glaucoma
    - 11.4.4 Cardiovascular Disease
    - 11.4.5 Diabetes
    - 11.4.6 Others
  - 11.5 By Workflow
    - 11.5.1 Clinical
    - 11.5.2 Commercial
  - 11.5 Brazil
  - 11.6 Mexico
  - 11.7 Argentina
  - 11.8 Chile
  - 11.9 Colombia
  - 11.10 Rest of LATAM
- 12 Competitive Landscape
  - 12.1 Global Active Pharmaceutical Ingredients CDMO Market Share By Players
  - 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
  - 13.1 American International Industries (GIGI)
    - 13.1.1 Overview
    - 13.1.2 Business Information
    - 13.1.3 Revenue
    - 13.1.4 ASP
    - 13.1.5 Swot Analysis
    - 13.1.6 Recent Developments
  - 13.2 Recipharm AB
  - 13.3 Thermo Fisher Scientific Inc. (Pantheon)
  - 13.4 Corden Pharma International

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.5 Samsung Biologics
- 13.6 Lonza Group
- 13.7 Catalent, Inc.
- 13.8 Siegfried Holding AG
- 13.9 Piramal Pharma Solutions
- 13.10 Boehringer Ingelheim
- 14 Research Methodology
  - 14.1 Research Data
    - 14.1.1 Secondary Data
      - 14.1.1.1 Major secondary sources
      - 14.1.1.2 Key data from secondary sources
    - 14.1.2 Primary Data
      - 14.1.2.1 Key data from primary sources
      - 14.1.2.2 Breakdown of primaries
    - 14.1.3 Secondary And Primary Research
      - 14.1.3.1 Key industry insights
  - 14.2 Market Size Estimation
    - 14.2.1 Bottom-Up Approach
    - 14.2.2 Top-Down Approach
    - 14.2.3 Market Projection
  - 14.3 Research Assumptions
    - 14.3.1 Assumptions
  - 14.4 Limitations
  - 14.5 Risk Assessment
- 15 Appendix
  - 15.1 Discussion Guide
  - 15.2 Customization Options
  - 15.3 Related Reports
- 16 Disclaimer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, Antibody Drug Conjugate, Others), By Synthesis (Synthetic, Biotech), By Drug (Innovative, Generics), By Applications (Oncology, Hormonal, Glaucoma, Cardiovascular Disease, Diabetes, Others), By Workflow (Clinical, Commercial) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031**

Market Report | 2023-04-06 | 0 pages | Straits Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-22"/>
		Signature	<input type="text"/>